Navigation Links
Chimerix to Present at Cowen and Company's 32nd Annual Health Care Conference
Date:3/5/2012

vir-diphosphate and has broad spectrum activity against dsDNA viruses in vitro. CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV and is in Phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant recipients. Antiviral activity results from completed and ongoing studies, coupled with the lack of myelotoxicity and nephrotoxicity seen in currently available therapies, indicate that CMX001 has the potential to improve outcomes for immunosuppressed patients. To date, more than 700 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.

In addition to the company's development of its lead candidate, CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, with the potential to provide an important therapeutic option for the 80 million people in the US currently estimated to be immunocompromised, or a household contact of a contraindicated individual, and thus not candidates to receive a smallpox vaccine (see http://www.bt.cdc.gov/agent/smallpox/vaccination/contraindications-clinic.asp). Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. U01-A1057233 and from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

Chimerix's second clinical-stage antiviral compound, CMX157, is a Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent tenofovir-diphosphate. CMX157 is in development as a potent nucleoside analogue against HIV and
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015  Only a quarter of physicians ... the patients they prescribe them to, according to new ... of Medicine (BUSM) and myCME , Haymarket ... Daniel Alford, M.D. , director of BUSM,s Safe ... , said, "This indicates a critical need for provider ...
(Date:6/2/2015)... , June 2, 2015  ErgoNurse, the leader in ... of healthcare products in the United States ... nursing home, long-term care and skilled nursing markets. ... ... able to fully take advantage of the ErgoNurse products to ...
(Date:6/2/2015)...  CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached an agreement to settle the ... Court of Chancery, which names as defendants ... and officers, and names the Company as a nominal ... CytRx Corp. Stockholder Derivative Litigation , C.A. No. 9864-VCL, ...
Breaking Medicine Technology:Survey Results Show Few Doctors Are Very Confident Managing Patients on Opioids 2ErgoNurse and Briggs Healthcare Positioned to Completely Eliminate the Unnecessary Cost of Healthcare-Related Back Injuries 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4
(Date:6/2/2015)... Though almost the entire Park family was born ... rule their lives. Organizing and hosting the June 14 event ... to the fullest and spreading awareness of HHT. , “I've ... won't live my life in a bubble because something bad ... is to look back on your life with regret because ...
(Date:6/2/2015)... 02, 2015 Vancouver, BC – ... Research ( http://www.idataresearch.com ), the bone graft substitute ... matrices (DBM) over traditional allograft materials. Because the ... thus an increase in operation time, alternative graft ... growth in these synthetic materials is partly the ...
(Date:6/2/2015)... Recent findings from the 2014 National Youth ... a reduction in conventional cigarette smoking, use of electronic ... has doubled among today’s teens in a year. ... national trend is consistent with what is occurring locally, ... to fully determine the long-term effects of e-cigarette usage ...
(Date:6/2/2015)... PhishLine, LLC today announced it ... Drive, Suite 125 in Waukesha, Wisconsin 53186. ... base of operations for PhishLine’s current corporate staff ... , Mark Chapman, Founder and President, commented “PhishLine ... enterprise customers adopt our market leading service to ...
(Date:6/2/2015)... 2015 Mercy Health (formerly Catholic Health ... Kentucky – has devoted the seventh of its monthly ... cancer prevention. One in five Americans will get skin ... YouTube channel, a Mercy Health expert addresses these skin ... causes of skin cancer? ,     What are the ...
Breaking Medicine News(10 mins):Health News:Family brings awareness to genetic disease at first Memphis walk 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 3Health News:Susquehanna Health Pediatrician Warns of Adverse Effects of Teen E-Cigarette Usage 2Health News:Susquehanna Health Pediatrician Warns of Adverse Effects of Teen E-Cigarette Usage 3Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Video provides helpful information about skin cancer prevention 2
... constipation are more likely to get diagnosed with the progressive ... have// some effect on the function of the gut long ... led the research, said: "It could help us more effectively ... high risk of developing the disease in the future." The ...
... type of childhood brain cancer has a unique molecule ... fight it.// Armed with targeted molecular treatments, doctors may ... side effects of prolonged and powerful radiation and chemotherapy ... a collaborative effort looking at a type of childhood ...
... A new invenvtion in the medical history. A team of ... a 68-year old woman using a remote controlled robot. This ... medical history. The operation took place at the European Institute ... it is a phenomenal step and we cannot even begin ...
... the Institute of Health Sciences in Oxford found that women ... to have a stillbirth, or to develop pre-eclampsia.// Taking low-dose ... researchers. ,The researchers reviewed more than 23 previous ... of anti-platelet drugs, of which low-dose aspirin is the most ...
... errors in the alpha gene are the cause of premature ... affects about 2% of the total population.// ,The University ... development of a genetic test, which would allow women with ... are at risk. They analysed DNA from women who had ...
... and marketing rights of the anti-anthrax vaccine developed by the ... is expected that the vaccine would be in the market ... to JNU for the exclusive rights. In addition, it will ... is yet to make any projections on the business the ...
Cached Medicine News:
... is a solid solution for ... package includes the Vibratome Plus, ... blocks, v-block adapter, specimen mounts ... stage assembly for ease in ...
... Vibratome Semi-Automatic Tissue Sectioning System has maintained ... sectioning system. Researchers from around the globe ... for their fresh and fresh fixed tissue ... With the Vibratome Automatic Tissue Sectioning ...
... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
... NEW Vibratome 3000 Plus Sectioning System provides ... fixed, animal, or plant tissues. The ... allows sectioning without freezing or embedding. ... morphology, the destruction of enzyme activities, and ...
Medicine Products: